Genic Co. Ltd (123330) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Genic Co. Ltd stock KRW 26,310, price KRW 14,340, upside +83.5%, quality 79 out of 100. Rating: strongly undervalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 3,060 KRW – 42,600 KRW · fair‑value band 20,268 KRW – 33,199 KRW · the 14,340 KRW price screens below the 26,310 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Genic Co. in your weekly email
Every Wednesday you see whether Genic Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Genic Co., Ltd. researches, develops, manufactures, and sells cosmetics and pharmaceuticals in South Korea and internationally.
Show moreShow less
The company provides hydrogel masks, sheet masks, cream wrapping masks, mud masks, and bio cellulose masks; nose patch, eye patch, body patch, eye gel, lifting patch, and outdoor patches; cleanser, toner, lotion, serum, cream, sunscreen, and cleansing/soothing/oil pad; and shampoo and tonic.
It offers its products under the CELEDERMA, CELEDERMA daily, and Excuse my Frank brands. Genic Co., Ltd. was founded in 2001 and is headquartered in Seongnam-si, South Korea.
Stock analysis
Genic Co. Ltd (123330) currently trades at 14,340 KRW, while our model-based Fair Value estimate is 26,310 KRW, implying the stock looks roughly 45% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 38,937 KRW per share, and 19 of the 22 models we run sit above the 14,340 KRW price.
Bear case: the Economic Profit group reads lowest at 14,356 KRW, and 3 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 20,268 KRW (bear) to 33,199 KRW (bull), the price of 14,340 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 79/100 (high quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Genic Co. Ltd reported revenue of 78.2B KRW in FY2025 versus 38.4B KRW in FY2021, a compound +19.5%/yr. Reported net income was 18.9B KRW in FY2025.
Key figures
Market cap 112B KRW (≈ $82.5M) Micro · P/E ratio 4.3 · P/S ratio 1.01 · EPS (TTM) 3,331 KRW · Net margin 22.8% · Return on equity 61.0% · Return on assets (EBIT) 1.0% (5-year average) · Operating margin 20.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 82 out of 100 (medium confidence).
What moves the price
The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 83%, 123330 screens cheaper than that median.
Fair Value models
Bear20,268 KRWFair Value 26,310 KRWBull33,199 KRW
Price 14,340 KRW · Upside +83.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2,856 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.98/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+56.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Start year 2020 (pandemic). Over 10 years: +0.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.5% (2020) → 19.2% (2025)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−8.2%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −10.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 11/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score79 · Top 25%
Fair Value upside+76.9% · Top 25%
Profitability
Return on equity (12 months)61.0% · Top 25%
Return on assets33.4% · Top 25%
Net margin (12 months)22.8% · Top 25%
Operating margin (12 months)20.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)99.6% · Top 25%
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Genic Co. Ltd (123330) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 26,310 KRW versus a price of 14,340 KRW, about +83% upside (undervalued).
What is the fair value of 123330?
Our model-based fair value for Genic Co. Ltd is 26,310 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 14,340 KRW.
What is the quality score of 123330?
Genic Co. Ltd has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genic Co. Ltd (123330)?
Our model-based price target is the fair value of 26,310 KRW (as of Nov 9, 2026) from 22 valuation models. Cautious scenario 20,268 KRW, optimistic scenario 33,199 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Genic Co. Ltd stock forecast for 2026?
Our models put fair value at 26,310 KRW, about +83% upside versus a price of 14,340 KRW (undervalued). Cautious scenario 20,268 KRW, optimistic scenario 33,199 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genic Co. Ltd (123330)?
Genic Co. Ltd reported trailing-twelve-month revenue of about 114B KRW (latest available figure, as of Nov 9, 2026).
What growth is priced into Genic Co. Ltd (123330)?
For today's price to be fair in a discounted-cash-flow model, Genic Co. Ltd would have to grow free cash flow by -8.2 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.2 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 123330 use?
Our models discount Genic Co. Ltd at 11.6 %: a base by market capitalisation (micro), damped by beta 0.47, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Genic Co. Ltd that is -8.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Genic Co. Ltd (123330) delivered so far?
Over the past 5 years revenue at Genic Co. Ltd grew +13.2 % a year. The price currently implies free-cash-flow growth of -8.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Genic Co. Ltd (123330) growing?
The median revenue growth in the sector is +3.6 % a year. That is the yardstick for the growth priced into Genic Co. Ltd (-8.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Genic Co. Ltd (123330)?
The free-cash-flow yield on the price is 16.01 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Genic Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Genic Co. Ltd (123330)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genic Co. Ltd it is 26,310 KRW per share (as of Nov 9, 2026), against a price of 14,340 KRW. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Genic Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 123330 trades below its calculated fair value: price 14,340 KRW, fair value 26,310 KRW, a gap of about +83% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 123330?
No. The price is what the market pays today (14,340 KRW); the fair value is what the company's own numbers justify (26,310 KRW). For Genic Co. Ltd the two are 11,970 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genic Co. Ltd worth?
The market values Genic Co. Ltd at about 112B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 14,340 KRW; our models calculate a fair value of 26,310 KRW per share.
What do the bullish and bearish scenarios say about 123330?
Our models span a range for Genic Co. Ltd: cautious scenario 20,268 KRW, base 26,310 KRW, optimistic 33,199 KRW per share (as of Nov 9, 2026, price 14,340 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 123330?
Genic Co. Ltd trades at a price-to-earnings ratio of 4.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 26,310 KRW is built from several models across several years. Other multiples: P/B 2.8, P/S 1.0, EV/EBITDA 4.7.
How solid is the balance sheet of Genic Co. Ltd (123330)?
Balance-sheet figures for Genic Co. Ltd (as of Nov 9, 2026): return on equity 61.0%. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is 123330 from its 52-week high?
Genic Co. Ltd trades at 14,340 KRW, about 61% below its 52-week high of 36,900 KRW and at the low of 14,340 KRW (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 26,310 KRW is for.
Which stocks are comparable to Genic Co. Ltd?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genic Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 14,340 KRW, calculated fair value 26,310 KRW (+83%), Quality Score 79/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 123330 calculated?
We run Genic Co. Ltd through 22 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 26,310 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Genic Co. Ltd currently trades 45% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genic Co. Ltd (123330)?
The closing price on Nov 9, 2026 was 14,340 KRW. Our model-based fair value is 26,310 KRW, about +83% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genic Co. Ltd right now?
The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (20,268 KRW). The market is more pessimistic than our downside scenario.
Key figures of Genic Co. Ltd
How large is the market capitalisation of Genic Co. Ltd (123330)?
The market capitalisation of Genic Co. Ltd is 112B KRW (≈ $82.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genic Co. Ltd (123330)?
The price-to-sales ratio of Genic Co. Ltd is 1.01 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genic Co. Ltd (123330)?
Earnings per share at Genic Co. Ltd are 3,331 KRW (price ÷ EPS = P/E 4.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genic Co. Ltd (123330)?
The net margin of Genic Co. Ltd is 22.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genic Co. Ltd (123330)?
The return on equity (ROE) of Genic Co. Ltd is 61.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genic Co. Ltd (123330)?
On an EBIT basis the return on assets of Genic Co. Ltd is 1.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genic Co. Ltd (123330)?
The operating margin of Genic Co. Ltd is 20.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genic Co. Ltd (123330)?
Revenue at Genic Co. Ltd is growing +99.6% versus a year earlier (3y avg +35.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Genic Co. Ltd (123330)?
Earnings per share at Genic Co. Ltd are growing +180% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Genic Co. Ltd (123330) carry?
The net debt of Genic Co. Ltd is 3.7B KRW (fiscal year 2024, ≈ 0.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Genic Co. Ltd in the live analysis
One click puts Genic Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026